Soluble Triggering Receptor Expressed on Myeloid Cell-1 (sTREM-1): A New Mediator Involved in Early Ankylosing Spondylitis

Objective To investigate the possible role of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) in ankylosing spondylitis (AS). Methods Serum sTREM-1 levels were measured in 80 patients with AS and 30 healthy controls, and synovial fluid (SF) sTREM-1 levels were tested in 6 AS patie...

Full description

Saved in:
Bibliographic Details
Published in:Journal of rheumatology 2008-09, Vol.35 (9), p.1846-1848
Main Authors: CHEN, Chun-Hsiung, LIAO, Hsien-Tzung, CHEN, Hung-An, LIANG, Toong-Hua, WANG, Chin-Tien, CHOU, Chung-Tei
Format: Article
Language:English
Subjects:
Adult
Biological and medical sciences
Biomarkers - blood
Diseases of the osteoarticular system
Diseases of the spine
Female
Health Status
Humans
Inflammation Mediators - blood
Inflammatory joint diseases
Male
Medical sciences
Membrane Glycoproteins - blood
Receptors, Immunologic - blood
Severity of Illness Index
Spondylitis, Ankylosing - blood
Spondylitis, Ankylosing - diagnosis
Spondylitis, Ankylosing - physiopathology
Synovial Fluid - metabolism
Triggering Receptor Expressed on Myeloid Cells-1
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective To investigate the possible role of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) in ankylosing spondylitis (AS). Methods Serum sTREM-1 levels were measured in 80 patients with AS and 30 healthy controls, and synovial fluid (SF) sTREM-1 levels were tested in 6 AS patients using ELISA. Demographic data were collected, and patient’s disease activity (BASDAI), functional ability (BASFI), and global assessment (BAS-G) were evaluated. We also tested erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and IgA in these patients. Results Serum sTREM-1 levels were detectable (definition, ≥ 15 pg/ml) in 31.3% (25/80) of the AS patients, as compared to only 10% (3/30) of healthy controls (p = 0.027). SF sTREM-1 levels were detectable (≥ 15 pg/ml) in 83% (5/6) of the AS patients. The detectable rate of sTREM-1 in SF was significantly higher than in serum (p = 0.018). Disease duration was shorter in AS patients with “higher” serum sTREM-1 levels (≥ 30 pg/ml) versus those with “lower” levels (< 30 pg/ml) [mean (SD), 4.3 (3.7) vs 8.6 (7.8) yrs, p = 0.036], but the differences between these 2 groups of patients were not evident based on results of BASDAI, BASFI, BAS-G, ESR, CRP, or IgA levels. Of note, serum sTREM-1 levels inversely correlated with disease duration (r = −0.433, p = 0.03) in the 25 AS patients with detectable sTREM-1 levels. Conclusion sTREM-1 seems to be a new mediator involved in patients with AS, particularly in the early stages of disease. Key Indexing Terms: ANKYLOSING SPONDYLITIS SERUM SYNOVIAL FLUID DISEASE DURATION SOLUBLE TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELL-1
ISSN:0315-162X
1499-2752